Impact of weight gain on outcomes in type 2 diabetes

References

• Haslam DW, James WPT. Obesity. Lancet 2005;366:1197-209
   PubMed Web of Science ®Google Scholar
• World Cancer Research Fund, American Institute for Cancer Research (AICR). Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington, DC: AICR, 2007
   Google Scholar
• Burke GL, Bertoni AG, Shea S, et al. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. Arch Intern Med 2008;168:928-35
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Blackburn G, Brancati FL, et al. Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374-83
   PubMed Web of Science ®Google Scholar
• Whitlock G, Lewington S, Sherliker P, et al. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083-96
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X. The medical risks of obesity. Postgrad Med 2009;121:21-33
   PubMed Web of Science ®Google Scholar
• Abdullah A, Peeters A, de Courten M, et al. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract 2010;89:309-19
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Fox KM, Grandy S; for the SHIELD Study Group. Impact of obesity on work productivity and role disability in individuals with and at risk for diabetes mellitus. Am J Health Promot 2009;23:353-60
   PubMed Web of Science ®Google Scholar
• Goetzel RZ, Gibson TB, Short ME, et al. A multi-worksite analysis of the relationships among body mass index, medical utilization, and worker productivity. J Occup Environ Med 2010;52(Suppl 1):S52-8
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V, Ben-Joseph RH. The effect of obesity and cardiometabolic risk factors on expenditures and productivity in the United States. Obesity 2008;16:2155-62
   PubMed Web of Science ®Google Scholar
• Kushner RF, Sujak M. Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone. Obesity 2009;17:1017-22
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report. Washington, DC: National Institutes of Health, September 1998
   Google Scholar
• Fujimoto WY, Jablonski KA, Bray GA, et al. Diabetes Prevention Program Research Group. Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program. Diabetes 2007;56:1680-5
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al.Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50
   PubMed Web of Science ®Google Scholar
• Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses’ Health Study. Am J Epidemiol 1997;145:614-19
   PubMed Web of Science ®Google Scholar
• Conen D, Ridker PM, Mora S, et al. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J 2007;28:2937-43
   PubMed Web of Science ®Google Scholar
• Balthasar N. Feeding signals to the hungry mind. Exp Physiol 2009;94:857-66
   PubMed Web of Science ®Google Scholar
• Allison DB, Downey M, Atkinson RL, et al. TOS Obesity as a Disease Writing Group. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity 2008;16:1161-77
   PubMed Web of Science ®Google Scholar
• Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162:1867-72
   PubMed Web of Science ®Google Scholar
• Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001;161:1581-6
   PubMed Web of Science ®Google Scholar
• Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-105
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al.INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health 2005;59:134-9
   Google Scholar
• Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-9
   Google Scholar
• Anderson JW, Kendall CWC, Jenkins DJA. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9
   PubMed Web of Science ®Google Scholar
• Fox CS, Pencina MJ, Wilson PW, et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 2008;31:1582-4
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Flegal KM, Graubard BI, Williamson DF, et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007;298:2028-37
   PubMed Web of Science ®Google Scholar
• Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010;15:556-65
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38
   PubMed Web of Science ®Google Scholar
• Parr CL, Batty GD, Lam TH, et al. Asia-Pacific Cohort Studies Collaboration. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. Lancet Oncol 2010;11:741-52
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:4037-43
   PubMed Web of Science ®Google Scholar
• Pani LN, Nathan DM, Grant RW. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care 2008;31:386-90
   PubMed Web of Science ®Google Scholar
• Dale J, Martin S, Gadsby R. Insulin initiation in primary care patients with type 2 diabetes: 3-year follow-up study. Prim Care Diabetes 2010;4:85-9
   PubMed Web of Science ®Google Scholar
• Feldstein AC, Nichols GA, Smith DH, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care 2008;31:1960-5
   PubMed Web of Science ®Google Scholar
• Dixon J, O’Brien P, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes. JAMA 2008;299:316-32
   PubMed Web of Science ®Google Scholar
• Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-504
   PubMed Web of Science ®Google Scholar
• Lean ME, Powrie JK, Anderson AS, et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990;7:228-33
   PubMed Web of Science ®Google Scholar
• Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001;9(Suppl 4):326S-34S
   PubMedGoogle Scholar
• DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270-87
   PubMed Web of Science ®Google Scholar
• Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med 2009;150:803-8
   PubMed Web of Science ®Google Scholar
• Hollander P. Anti-diabetes and anti-obesity medications: effects on weight in people with diabetes. Diab Spect 2007;20:159-65
   Google Scholar
• United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8
   PubMed Web of Science ®Google Scholar
• Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410-18
   PubMed Web of Science ®Google Scholar
• Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-85
   PubMed Web of Science ®Google Scholar
• Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009;52:1990-2000
   PubMed Web of Science ®Google Scholar
• Holman RR, Farmer AJ, Davies MJ, et al. 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47
   PubMed Web of Science ®Google Scholar
• Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Tech Assess 2010;14:1-268
   Web of Science ®Google Scholar
• Hermansen K, Lund P, Clemmensen K, et al. on behalf of the Danish PREDICTIVE study group. 3-Month results from Denmark within the globally prospective and observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes: The PREDICTIVE Study. Rev Diabet Stud 2007;4:89-97
   PubMedGoogle Scholar
• Dornhurst A, Luddeke H-J, Sreenan S, et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008;62:4:659-65
   PubMed Web of Science ®Google Scholar
• Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta 2010;1801:311-19
   PubMed Web of Science ®Google Scholar
• Chavez JA, Summers SA. Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. Biochim Biophys Acta 2010;1801:252-65
   PubMed Web of Science ®Google Scholar
• Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22:288-93
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-91
   PubMed Web of Science ®Google Scholar
• Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003;26:3148-52
   PubMed Web of Science ®Google Scholar
• Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006;29:510-14
   PubMed Web of Science ®Google Scholar
• Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 2008;37:603-21
   PubMed Web of Science ®Google Scholar
• Hamlat N, Forcheron F, Negazzi S, et al. Lipogenesis in arterial wall and vascular smooth muscular cells: regulation and abnormalities in insulin-resistance. Cardiovasc Diabetol 2009;8:64
   PubMedGoogle Scholar
• Gupta AK, Smith SR, Greenway FL, et al. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes Metab 2009;11:330-7
   PubMed Web of Science ®Google Scholar
• Yang Y, Thumula V, Pace PF, et al. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther 2009;31:2178-88
   PubMed Web of Science ®Google Scholar
• Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004;27:2149-53
   PubMed Web of Science ®Google Scholar
• Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002;19:279-84
   PubMed Web of Science ®Google Scholar
• Freeman JS. New therapeutic options: management strategies to optimize glycemic control. J Am Osteopath Assoc 2010;110(3 Suppl 2):S15-20
   PubMedGoogle Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl 3):S18-S24
   PubMed Web of Science ®Google Scholar
• Mosnier-Pudar H, Hochberg G, Eschwege E, et al. How patients’ attitudes and opinions influence self-care behaviours in type 2 diabetes. Insights from the French DIABASIS Survey. Diabetes Metab 2010;36(6 Pt 1):476-83
   PubMed Web of Science ®Google Scholar
• Brod M, Cobden D, Lammert M, et al. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes 2007;5:8
   PubMed Web of Science ®Google Scholar
• Hauber AB, Mohamed AF, Johnson FR, et al. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med 2009;26:416-24
   PubMed Web of Science ®Google Scholar